Free Trial
NASDAQ:ROIV

Roivant Sciences (ROIV) Stock Price, News & Analysis

Roivant Sciences logo
$11.42 +0.20 (+1.74%)
As of 02:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Roivant Sciences Stock (NASDAQ:ROIV)

Key Stats

Today's Range
$11.19
$11.46
50-Day Range
$10.62
$11.60
52-Week Range
$8.73
$13.06
Volume
2.99 million shs
Average Volume
5.75 million shs
Market Capitalization
$7.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.88
Consensus Rating
Buy

Company Overview

Roivant Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

ROIV MarketRank™: 

Roivant Sciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 769th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Roivant Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Roivant Sciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Roivant Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Roivant Sciences are expected to decrease in the coming year, from ($0.92) to ($1.27) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Roivant Sciences is -45.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Roivant Sciences is -45.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Roivant Sciences has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Roivant Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    10.75% of the float of Roivant Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Roivant Sciences has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Roivant Sciences has recently increased by 1.42%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Roivant Sciences does not currently pay a dividend.

  • Dividend Growth

    Roivant Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.75% of the float of Roivant Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Roivant Sciences has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Roivant Sciences has recently increased by 1.42%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Roivant Sciences has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Roivant Sciences this week, compared to 7 articles on an average week.
  • Search Interest

    7 people have searched for ROIV on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Roivant Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,098,856.00 in company stock.

  • Percentage Held by Insiders

    Only 7.90% of the stock of Roivant Sciences is held by insiders.

  • Percentage Held by Institutions

    64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Roivant Sciences' insider trading history.
Receive ROIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter.

ROIV Stock News Headlines

Which Gold Miner Trades at 30% of NAV? The One Buffett Wants
Some of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. With gold at record highs and Bridgewater now buying in, one analyst believes Buffett’s next move could hit by August 15th. He’s identified the gold miner that fits Buffett’s profile — plus four smaller plays with even more upside.
Roivant Sciences Ltd. (ROIV) - Yahoo Finance
See More Headlines

ROIV Stock Analysis - Frequently Asked Questions

Roivant Sciences' stock was trading at $11.83 at the beginning of the year. Since then, ROIV stock has decreased by 4.1% and is now trading at $11.3450.

Roivant Sciences Ltd. (NASDAQ:ROIV) released its quarterly earnings data on Thursday, May, 29th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.15. The firm earned $7.57 million during the quarter, compared to analyst estimates of $62.17 million. Roivant Sciences had a negative trailing twelve-month return on equity of 14.76% and a negative net margin of 225.71%.
Read the conference call transcript
.

Roivant Sciences' top institutional shareholders include Peak Financial Advisors LLC (0.01%) and Wedmont Private Capital. Insiders that own company stock include Pharma Technologies Ltd Dexcel, Sciences Ltd Roivant, Svf Investments (Uk) Ltd, Vivek Ramaswamy, Financial Lp Qvt, Mayukh Sukhatme, Matthew Gline, Eric Venker, Keith S Manchester, Global Investors Lp Viking, Richard Pulik and Rakhi Kumar.
View institutional ownership trends
.

Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Roivant Sciences investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/29/2025
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ROIV
CIK
1635088
Fax
N/A
Employees
860
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$12.50
Potential Upside/Downside
+35.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$171.98 million
Net Margins
-225.71%
Pretax Margin
-2,346.02%

Debt

Sales & Book Value

Annual Sales
$29.05 million
Price / Cash Flow
N/A
Book Value
$7.45 per share
Price / Book
1.51

Miscellaneous

Free Float
626,101,000
Market Cap
$7.63 billion
Optionable
Optionable
Beta
1.15
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ROIV) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners